Goldman Sachs
NBP

Goldman Sachs’s NovaBridge Biosciences American Depositary Shares NBP Stock Holding History

Goldman Sachs’s Portfolio NBP Stock Details NBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$315K Buy
161,321
+48,858
+43% +$99.6K ﹤0.01% 5985
2026
Q1 		$277K Sell
112,463
-28,483
-20% -$95.3K ﹤0.01% 5937
2025
Q4 		$561K Sell
140,946
-77,524
-35% -$343K ﹤0.01% 5520
2025
Q3 		$826K Buy
218,470
+207,788
+1,945% +$705K ﹤0.01% 5162
2025
Q2 		$25.9K Sell
10,682
-3
-0% -$4 ﹤0.01% 5961
2025
Q1 		$8.8K Hold
10,685
– – ﹤0.01% 5975
2024
Q4 		$9.08K Hold
10,685
– – ﹤0.01% 5933
2024
Q3 		$13.2K Sell
10,685
-5,065
-32% -$6.34K ﹤0.01% 5692
2024
Q2 		$26.3K Sell
15,750
-69,191
-81% -$124K ﹤0.01% 5504
2024
Q1 		$158K Sell
84,941
-60,254
-41% -$111K ﹤0.01% 5172
2023
Q4 		$276K Sell
145,195
-96,176
-40% -$144K ﹤0.01% 5043
2023
Q3 		$319K Sell
241,371
-53,162
-18% -$117K ﹤0.01% 4872
2023
Q2 		$881K Sell
294,533
-64,587
-18% -$207K ﹤0.01% 4438
2023
Q1 		$1.24M Sell
359,120
-173,360
-33% -$840K ﹤0.01% 4226
2022
Q4 		$2.23M Sell
532,480
-605,858
-53% -$2.29M ﹤0.01% 3859
2022
Q3 		$4.57M Buy
1,138,338
+59,143
+5% +$449K ﹤0.01% 3207
2022
Q2 		$12.2M Buy
1,079,195
+352,503
+49% +$4.23M ﹤0.01% 2319
2022
Q1 		$11.8M Buy
726,692
+360,273
+98% +$9.23M ﹤0.01% 2520
2021
Q4 		$17.4M Buy
366,419
+155,858
+74% +$9.35M ﹤0.01% 2253
2021
Q3 		$15.3M Buy
210,561
+69,489
+49% +$5.03M ﹤0.01% 2313
2021
Q2 		$11.8M Sell
141,072
-7,530
-5% -$497K ﹤0.01% 2528
2021
Q1 		$7.2M Buy
148,602
+132,595
+828% +$7.19M ﹤0.01% 2827
2020
Q4 		$755K Sell
16,007
-40,899
-72% -$1.61M ﹤0.01% 4381
2020
Q3 		$2.68M Buy
+56,906
New +$1.88M ﹤0.01% 3359

Other funds holding NBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACM
AIHC Capital Management Central $104M AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs's NBP Position: Q2 2026 in Review

Goldman Sachs increased its NovaBridge Biosciences American Depositary Shares (NBP) stake by 43% in Q2 2026, buying an estimated $99.6K and bringing the position to 161,321 shares worth $315K. The position accounts for ﹤0.01% of the portfolio, ranked #5985.

Goldman Sachs first reported a position in NBP in Q3 2020 and has held it in 24 quarters since. The position peaked at $17.4M in Q4 2021. 49 funds tracked by Wall St. Rank hold NBP as of Q2 2026.

  • Goldman Sachs held 161,321 shares of NovaBridge Biosciences American Depositary Shares worth $315K as of Q2 2026.
  • Goldman Sachs bought 48,858 NovaBridge Biosciences American Depositary Shares shares in Q2 2026, an estimated $99.6K.
  • NovaBridge Biosciences American Depositary Shares made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5985 holding.
  • Goldman Sachs first reported a position in NovaBridge Biosciences American Depositary Shares in Q3 2020 and has held it in 24 quarters since.
  • Goldman Sachs's NovaBridge Biosciences American Depositary Shares position peaked at $17.4M in Q4 2021.
  • 49 funds tracked by Wall St. Rank held NovaBridge Biosciences American Depositary Shares as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.